Sexualhormone

  • Ulrich Schwabe
  • Thomas Rabe

Zusammenfassung

Die wichtigsten Gruppen der Sexualhormone sind Östrogenpräparate und die Kontrazeptiva.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Castelo-Branco C., Vicente J.J., Figueras F,. Sanjuan A., Martinez de Osaba M.J., Casals E. et al. (2000): Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas 34: 161–168.PubMedCrossRefGoogle Scholar
  2. Cauley J.A., Black D.M., Barrett-Connor E., Harris F., Shields K., Applegate W., Cummings S.R. (2001): Effects of hormone replacement therapy on clinical fractures and height loss: the heart and estrogen/Progestin replacement study (HERS). Am. J. Med. 110: 442–450.PubMedCrossRefGoogle Scholar
  3. Cauley J.A., Seeley D.G., Ensrud K., Ettinger B., Black D., Cummings S.R. (1995): Estrogen replacement therapy and fractures in older women. Ann. Intern. Med. 122: 9–16.PubMedCrossRefGoogle Scholar
  4. Colditz G.A., Hankinson S.E., Hunter D.J., Willett W.C., Manson J.E. et al. (1995): The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N. Engl. J. Med. 332: 1589–1593.PubMedCrossRefGoogle Scholar
  5. Collaborative Group on Hormonal Factors in Breast Cancer (1997): Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 350: 1047–1059.CrossRefGoogle Scholar
  6. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K. et al. for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators (1999): Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282: 637–645.PubMedCrossRefGoogle Scholar
  7. Farish E., Barnes J.F., Fletcher C.D., Ekevall K., Calder A., Hart D.M. (1999): Effects of tibolone on serum lipoprotein and apolipoprotein levels compared with a cyclical estrogen/progesteron regimen. Menopause 6: 98–104.PubMedCrossRefGoogle Scholar
  8. Fisher B., Constantino J.P., Wickerham L.D., Redmond C.K. et al. (1998): Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer I. 90: 1371–1388.CrossRefGoogle Scholar
  9. Grady D. (2002): A 60-year-old woman trying to discontinue hormone replacement therapy. JAMA 287: 2130–2137.PubMedCrossRefGoogle Scholar
  10. Grodstein F., Manson J.E., Colditz G.A., Willett W.C., Speizer F.E., Stampfer M.J. (2000): A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann. Intern. Med. 133: 933–1001.PubMedCrossRefGoogle Scholar
  11. Herrington D.M., Reboussin D.M., Brosnihan K. B., Sharp P.C., Shumaker S.A., Snyder T.E. et al. (2000): Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N. Engl. J. Med. 343: 522–529.PubMedCrossRefGoogle Scholar
  12. Hully S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., Vittinghoff E. (1998): Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280: 605–613.CrossRefGoogle Scholar
  13. Jick H., lick S.S., Gurewich V., Myers M.W., Vasilakis C. (1995): Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346: 1589–1593.PubMedCrossRefGoogle Scholar
  14. Katz S., Morales A.J. (1998): Dehydroepiandrosterone (DHEA) and DHEA-sulfate (DS) as therapeutic options in menopause. Semin. Reprod. Endocrinol. 16: 161–170.PubMedCrossRefGoogle Scholar
  15. Keating N.L., Cleary P.D., Rossi A.S., Zaslaysky A.M.,Ayanian J.Z. (1999): Use of hormone replacement therapy by postmenopausal women in the United States. Ann. Intern. Med. 130: 545–553.PubMedCrossRefGoogle Scholar
  16. Kemmeren J.M., Algra A., Grobbee D.E. (2001): Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. Brit. Med. J. 323: 1–9.CrossRefGoogle Scholar
  17. König H.J. (1991): Hirnkreislaufstörungen unter Einnahme gestodenhaltiger hormonaler oraler Kontrazeptiva - Kausalität oder Koinzidenz? Dtsch. Ärztebl. 91: C-1745–1748.Google Scholar
  18. Lamberts S.W., van den Beld A.W., van der Lely A.J. (1997): The endocrinology of aging. Science 278: 419–424.PubMedCrossRefGoogle Scholar
  19. Manson J.E., Martin K.A. (2001): Postmenopausal hormone-replacement therapy. N. Engl. J. Med. 345: 34–40.PubMedCrossRefGoogle Scholar
  20. Mosca L., Collins P., Herrington D.M., Mendelsohn M.E., Pasternak R.C., Robertson R.M. et al. (2001): Hormone replacement therapy and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation 104: 499–503.PubMedCrossRefGoogle Scholar
  21. Mulnard R.A., Cotman C.W., Kawas C., van Dyck C.H., Sano M., Doody R. et al. (2000): Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer’s Disease Cooperative Study. JAMA 283: 1007–1015.PubMedCrossRefGoogle Scholar
  22. Oelkers W., Helmerhorst F.M., Wuttke W., Heithecker R. (2000): Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers. Gynecol. Endocrinol. 14: 204–213.PubMedCrossRefGoogle Scholar
  23. Powles T., Eeles R., Ashley S., Easton D., Chang J. et al. (1998): Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital Tamoxifen randomised Chemoprevention Trial. Lancet 352: 98–101.PubMedGoogle Scholar
  24. Royal College of General Practitioners Oral Contraception Study (1981): Further analysis of mortality in oral contraceptive users. Lancet I: 541–546.Google Scholar
  25. Schairer C., Lubin J., Troisi R., Sturgeon S., Brinton L., Hoover R. (2000): Menopausal estrogen and estsrogen-progestin replacement therapy and breast cancer risk. JAMA 283: 485–491.PubMedCrossRefGoogle Scholar
  26. Spitzer W.O., Lewis M.A., Heinemann L.A.J., Thorogood M., MacRae K.D. (1996): Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Brit. Med. J. 312: 83–88.PubMedCrossRefGoogle Scholar
  27. Tang M.-X., Jacobs D., Stern Y., Marder K., Schofield P., Gurland B., Andrews H. (1996): Effect of oestrogen during menopause on risk and age at onset of Alzheimer’s disease. Lancet 348: 429–432.PubMedCrossRefGoogle Scholar
  28. Thiel C., Heinemann L.A. for the German Cohort Study on Women’s Health (2001): Reasons for the change in HRT therapy from the perspective of women. Results of the German Cohort Study on Women’s Health. Zentralbl. Gynäkol. 123: 390–398.PubMedCrossRefGoogle Scholar
  29. Veronesi U., Maisonneuve P., Costa A., Saccini V. Maltoni C. et al. on behalf of the Italian Tamoxifen Prevention Study (1998): Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial amoung hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 352: 93–97.PubMedGoogle Scholar
  30. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1995): Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 346: 1582–1588.Google Scholar
  31. Writing Group for the Women’s Health Initiative (2002): Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288: 321–333.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • Ulrich Schwabe
  • Thomas Rabe

There are no affiliations available

Personalised recommendations